Antigenics Improves Oncophage Vaccine Manufacturing Output Ahead Of Registration Trial
Non-registration Phase III trial shows extension in survival for Oncophage-treated arm in category M1a stage IV melanoma.
Non-registration Phase III trial shows extension in survival for Oncophage-treated arm in category M1a stage IV melanoma.